Disease · MONDO_0010526
Comparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 11 of 11
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Lucerastat vs Placebo: deaths from any cause | 0 of 80 | 0 of 37 | 117 | NCT03425539 | Trial comparisons |
| Lucerastat vs Placebo: serious adverse events | 5 of 80 | 1 of 37 | 117 | NCT03425539 | Trial comparisons |
| PRX-102 (Pegunigalsidase Alfa) vs Agalsidase Beta: deaths from any cause | 0 of 52 | 0 of 25 | 77 | NCT02795676 | Trial comparisons |
| PRX-102 (Pegunigalsidase Alfa) vs Agalsidase Beta: serious adverse events | 8 of 52 | 6 of 25 | 77 | NCT02795676 | Trial comparisons |
| Lead-in Period (Fabrazyme) vs Treatment Period (AGA BETA BS): deaths from any cause | 0 of 20 | 0 of 19 | 39 | NCT05843916 | Trial comparisons |
| Lead-in Period (Fabrazyme) vs Treatment Period (AGA BETA BS): serious adverse events | 0 of 20 | 5 of 19 | 39 | NCT05843916 | Trial comparisons |
| Fabrazyme 0.5 mg/kg vs Fabrazyme 1.0 mg/kg: serious adverse events | 6 of 16 | 5 of 15 | 31 | NCT00701415 | Trial comparisons |
| Safety Population RB vs Transition Safety Population: serious adverse events | 2 of 17 | 2 of 11 | 28 | NCT00084084 | Trial comparisons |
| Pegunigalsidase Alfa Reporting Group vs Phenotypically Classic Fabry Patients: Gastrointestinal Symptoms Questionnaire - Severity of Abdominal Pain | 10 of 16 | 7 of 10 | 26 | NCT01678898 | Trial comparisons |
| Pegunigalsidase Alfa Reporting Group vs Phenotypically Classic Fabry Patients: Gastrointestinal Symptoms Questionnaire - Frequency of Abdominal Pain | 7 of 16 | 5 of 10 | 26 | NCT01678898 | Trial comparisons |
| Pegunigalsidase Alfa Reporting Group vs Phenotypically Classic Fabry Patients: Gastrointestinal Symptoms Questionnaire - Frequency of Diarrhea | 11 of 16 | 6 of 10 | 26 | NCT01678898 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0010526/comparisons